BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 34461606)

  • 21. NK-associated receptors on CD8 T cells from treatment-naive HIV-infected individuals: defective expression of CD56.
    Tarazona R; DelaRosa O; Casado JG; Torre-Cisneros J; Villanueva JL; Galiani MD; Peña J; Solana R
    AIDS; 2002 Jan; 16(2):197-200. PubMed ID: 11807303
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Histidine-rich glycoprotein augments natural killer cell function by modulating PD-1 expression via CLEC-1B.
    Nishimura Y; Wake H; Teshigawara K; Wang D; Sakaguchi M; Otsuka F; Nishibori M
    Pharmacol Res Perspect; 2019 Jun; 7(3):e00481. PubMed ID: 31143450
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Expansion of mixed immune cells using CD3/CD161 co-stimulation for the treatment of cancer.
    Tsumura R; Haruta M; Kuwano M; Yasunaga M
    Sci Rep; 2023 Apr; 13(1):6803. PubMed ID: 37100864
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The expression of killer cell inhibitory receptors on natural killer cells and activation status of CD4+ and CD8+ T cells in the decidua of normal and abnormal early pregnancies.
    Chao KH; Wu MY; Chen CD; Yang JH; Yang YS; Ho HN
    Hum Immunol; 1999 Sep; 60(9):791-7. PubMed ID: 10527385
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The dual-functional capability of cytokine-induced killer cells and application in tumor immunology.
    Zhang Q; Liu XY; Zhang T; Zhang XF; Zhao L; Long F; Liu ZK; Wang EH
    Hum Immunol; 2015 May; 76(5):385-91. PubMed ID: 25305457
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ex vivo expansion of natural killer cells from human peripheral blood mononuclear cells co-stimulated with anti-CD3 and anti-CD52 monoclonal antibodies.
    Masuyama J; Murakami T; Iwamoto S; Fujita S
    Cytotherapy; 2016 Jan; 18(1):80-90. PubMed ID: 26549384
    [TBL] [Abstract][Full Text] [Related]  

  • 27. CD56
    Wang H; Zeng Y; Zhang M; Ma H; Xu B; Jiang H; Wang J; Li G
    Hum Immunol; 2019 Oct; 80(10):871-877. PubMed ID: 31326139
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immunological changes in peripheral blood mononuclear cells of patients with metastatic renal cell carcinoma after low doses of subcutaneous immunotherapy with IFN-alpha-2b and IL-2.
    Moltó L; Carballido J; Manzano L; Martinez-Martin B; Esquivel F; Chafer J; Olivier C; Alvarez-Mon M
    J Immunother; 1999 May; 22(3):260-7. PubMed ID: 10335486
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Ex vivo expansion of CD56+ NK and NKT-like lymphocytes from peripheral blood mononuclear cells of patients with ovarian neoplasia.
    Alves PCM; De Angelo Andrade LAL; Petta CA; Lorand-Metze I; Derchain SF; Guimarães F
    Scand J Immunol; 2011 Sep; 74(3):244-252. PubMed ID: 21595734
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Functional and phenotypic assessment of neonatal human leucocytes expressing natural killer cell-associated antigens.
    Bradstock KF; Luxford C; Grimsley PG
    Immunol Cell Biol; 1993 Dec; 71 ( Pt 6)():535-42. PubMed ID: 7508887
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Natural killer-like T CD3+/CD16+CD56+ cells in chronic lymphocytic leukemia: intracellular cytokine expression and relationship with clinical outcome.
    Bojarska-Junak A; Hus I; Sieklucka M; Wasik-Szczepanek E; Mazurkiewicz T; Polak P; Dmoszynska A; Rolinski J
    Oncol Rep; 2010 Sep; 24(3):803-10. PubMed ID: 20664990
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dysfunction of natural killer cells mediated by PD-1 and Tim-3 pathway in anaplastic thyroid cancer.
    Yin M; Di G; Bian M
    Int Immunopharmacol; 2018 Nov; 64():333-339. PubMed ID: 30243069
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Induction of potent antitumour natural-killer cells from peripheral blood of patients with advanced prostate cancer.
    Oikawa T; Kawai K; Ishiwata I; Ohno T; Akaza H
    BJU Int; 2003 Dec; 92(9):1009-15. PubMed ID: 14632866
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Definition of a natural killer NKR-P1A+/CD56-/CD16- functionally immature human NK cell subset that differentiates in vitro in the presence of interleukin 12.
    Bennett IM; Zatsepina O; Zamai L; Azzoni L; Mikheeva T; Perussia B
    J Exp Med; 1996 Nov; 184(5):1845-56. PubMed ID: 8920872
    [TBL] [Abstract][Full Text] [Related]  

  • 35. PD-L1 targeting high-affinity NK (t-haNK) cells induce direct antitumor effects and target suppressive MDSC populations.
    Fabian KP; Padget MR; Donahue RN; Solocinski K; Robbins Y; Allen CT; Lee JH; Rabizadeh S; Soon-Shiong P; Schlom J; Hodge JW
    J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32439799
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Induction of CD16+ CD56bright NK cells with antitumour cytotoxicity not only from CD16- CD56bright NK Cells but also from CD16- CD56dim NK cells.
    Takahashi E; Kuranaga N; Satoh K; Habu Y; Shinomiya N; Asano T; Seki S; Hayakawa M
    Scand J Immunol; 2007 Feb; 65(2):126-38. PubMed ID: 17257217
    [TBL] [Abstract][Full Text] [Related]  

  • 37. PD1-CD28 Fusion Protein Enables CD4+ T Cell Help for Adoptive T Cell Therapy in Models of Pancreatic Cancer and Non-hodgkin Lymphoma.
    Rataj F; Kraus FBT; Chaloupka M; Grassmann S; Heise C; Cadilha BL; Duewell P; Endres S; Kobold S
    Front Immunol; 2018; 9():1955. PubMed ID: 30214445
    [No Abstract]   [Full Text] [Related]  

  • 38. Immunologic effects in patients with psoriatic arthritis treated with cyclosporine A.
    Boiardi L; Salvarani C; Macchioni P; Casadei Maldini M; Mancini R; Beltrandi E; Rossi F; Lodi L; Portioli I
    J Rheumatol; 1992 Dec; 19(12):1933-7. PubMed ID: 1284133
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Coexpression of Fc gamma receptor IIIA and interleukin-2 receptor beta chain by a subset of human CD3+/CD8+/CD11b+ lymphocytes.
    Zupo S; Azzoni L; Massara R; D'Amato A; Perussia B; Ferrarini M
    J Clin Immunol; 1993 May; 13(3):228-36. PubMed ID: 7686565
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immune phenotype of patients with stage IV metastatic inflammatory breast cancer.
    Fernandez SV; MacFarlane AW; Jillab M; Arisi MF; Yearley J; Annamalai L; Gong Y; Cai KQ; Alpaugh RK; Cristofanilli M; Campbell KS
    Breast Cancer Res; 2020 Dec; 22(1):134. PubMed ID: 33267869
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.